The vast majority of the 36.2 million individuals admitted to U.S. hospitals are diagnosed with hypertension and experience an elevated blood pressure (BP) reading during hospitalization. There are no guidelines for managing asymptomatically elevated BPs in the inpatient setting, and growing observational evidence suggests that antihypertensive medication intensification increases harm. The proposed study tests whether a unit-based intervention (ACT-BP) can reduce antihypertensive medication intensification and provides information that is scientifically necessary for designing a cluster-randomized clinical trial that identifies the impact of intensification after experiencing an asymptomatically elevated BP on patient outcomes.

Approximately 50-72% of the 36.2 million individuals admitted to U.S. hospitals are diagnosed with hypertension. Hypertension increases the risk of devastating cardiovascular outcomes, such as strokes, heart attacks, and heart failure. Three-quarters of admitted patients experience at least one elevated blood pressure (BP) (>140/90) during hospitalization. While BP is usually elevated for benign reasons, including pain and anxiety, acutely elevated BP can cause end-organ damage. Currently, no guidelines exist for managing asymptomatically elevated BP in the inpatient setting. There is growing observational evidence that antihypertensive medication intensification for asymptomatically elevated BP can result in adverse outcomes, such as increased readmission. Since observational studies are biased, a large-scale clinical trial is needed to identify whether to treat asymptomatically elevated BPs in the hospital. Yet, it would be unethical and costly to randomize individual patients to receive antihypertensive medication intensification. To overcome these obstacles, this study uses hospital-unit-level intervention, ACT-BP. ACT-BP removes standing orders to call physicians about elevated BPs (which encourages treatment due to social desirability bias), provides education on the potential harm of treating asymptomatically elevated BPs, and suggests alternative procedures (e.g., monitoring BP more frequently). At the end of the study, three specific pieces of knowledge needed to conduct a larger, adequately powered randomized clinical trial will be obtained. First, how much does ACT-BP reduce antihypertensive medication intensification? Second, what refinements will improve its effectiveness? Third, what is the rate of the composite outcome in the intervention and control units?

Inclusion Criteria:

• At the unit level: Medical units that do not typically care for patients requiring step-down care.

Exclusion Criteria:

1. Patients less than 18

2. Patients experiencing hypertensive emergencies or cardiac symptoms

3. Patients with active cardiovascular events, such as

   • Stroke
   • Non-ST-elevation
   • Myocardial infarction
   • End-stage renal disease
   • Patients on dialysis
   • Those with acute decompensated heart failure

3. Patients on the unit for more than 10 days

4. Patients transferred in after being in the intensive care unit (ICU)

5. Pregnant and post-partum women

6. Patients discharged within 24 hours of admission

7. Patients whose systolic BP remains below 160 mmHg during hospitalization.

De-identified data from the pilot trial will be deposited into a public repository.

At the end of the grant period (August 2027) the supporting information will be available and it will be available for 6 years.

The research community will have access to our findings at the end of the grant period. Since this is a short (2-year) grant, preliminary results will not be shared. The final dataset of de-identified quantitative results will be shared on Vivli, provided appropriate privacy safeguards are available. Alternatively, the de-identified data will be made available upon request under an FDP Data Use Agreement or similar transfer mechanism. Research can request the qualitative results directly from the Principal Investigator at Cleveland Clinic. Cleveland Clinic will consider each request on an individual basis, with combined input from the Principal Investigator, the Law Department, and the Institutional Review Board. Consistent with Cleveland Clinic policy, the data will be available for six years following the end of the grant period.